- Organizations: Tarsus Pharmaceuticals
Business
Tarsus to purchase Alkeus Pharmaceuticals
Second planned acquisition includes oral gildeuretinol acetate (ALK-001), a new molecular entity in phase 3 trials for Stargardt disease.
Business
Tarsus acquires iRenix Medical, adds late-stage ocular antiseptic
Company to initiate a phase 3 trial on IRX-101, an ocular antiseptic alternative to povidone-iodine among retinal patients receiving IVT injections.
Pipeline
Tarsus releases new phase 2 data on TP-03 for MGD
Latest findings on lotilaner ophthalmic solution, 0.25% reported during AAOpt demonstrate promise for improving gland function and reducing ocular itching and redness.
Business
Tarsus names Elizabeth Yeu, MD, as new chief medical officer
Dr. Yeu will lead the company’s new medical organization as it continues the rollout of XDEMVY for Demodex blepharitis.
Pipeline
Tarsus announces positive phase 2a topline data on TP-03 for MGD
Results demonstrate potential for TP-03 as a second indication to treat MGD with Demodex mites.
Products
Xdemvy officially launches in the US
Therapeutic is the first and only FDA-approved treatment for Demodex blepharitis.
Products
FDA approves Tarsus’s XDEMVY for Demodex blepharitis
Formerly known as TP-03, approval is the first that directly targets the root cause of the disease.
Research
Tarsus gets FDA acceptance on NDA for TP-03
The FDA has accepted Tarsus Pharmaceuticals’ New Drug Application (NDA) for TP-03, its therapy candidate designed to treat Demodex blepharitis
Archives